Clinical trials: Mild Cognitive Impairment(MCI)
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
- Trial name
- NCT01421056
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 6 sites in United States, Italy
- Volunteers
- 74 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Memory Impairment, Sleep Disorder
Improving Patient Memory for Treatment for Mild Cognitive Impairment
The main empirical question to be addressed is: What types of memory support are most potent for patients who are experiencing a mild cognitive impairment (MCI) relative to non-MCI patients?
- Trial name
- NCT05668481
- Testing
- Transdiagnostic sleep and circadian intervention (TranS-C)
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer Disease, Mild Cognitive Impairment
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients
Purpose of clinical trial; This clinical trial is designed to evaluate the effectiveness of 'NeuroAI' prediction accuracy compared to the amyloid PET test results by retrospectively collecting medical data of patients with mild…
- Trial name
- NCT05383053
- Testing
- NeuroAI
- Where
- South Korea
- Volunteers
- 227 people
- Sponsor
- Neurozen Inc.
Mild Cognitive Impairment (MCI)
Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months.
- Trial name
- MCI-GSH (NCT07583251)
- Testing
- Gamma- Glutamylcysteine, Gamma- Glutamylcusteine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Pravat Mandal
Mild Cognitive Impairment (MCI)
Evaluation of the Effect of Healthy Lifestyle Intervention for Patients With Mild Cognitive Impairment
This clinical study aims to evaluate the feasibility and preliminary effectiveness of a comprehensive lifestyle intervention program for patients with mild cognitive impairment.
- Trial name
- NCT06942780
- Testing
- Exercise intervention, Social intervention, Dietary intervention
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer Disease, Mild Cognitive Impairment
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease
This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Herpes Simplex
- Trial name
- VALZ-Pilot (NCT02997982)
- Testing
- Valaciclovir 500Mg Tablet
- Where
- 2 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- Hugo Lovheim
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Mild Cognitive Impairment (MCI), Cognition
LpD3.5 Intervention Study in Older Adults- LISA-I Trial
This randomized placebo-controlled clinical study, called the LpD3.5 Intervention Study in Older Adults (LISA), aims to evaluate whether a heat-inactivated postbiotic of human origin (LpD3.5) can serve as a non-pharmacological…
- Conditions
- Mild Cognitive Impairment (MCI), Cognition, Brain Aging, Microbiome Dysbiosis
- Trial name
- Postbiotics (NCT07794956)
- Testing
- LpD3.5
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Dementia, Primary Palliative Care
Supportive Care for Cognitively Impaired Patients and Families
Currently almost 5 million Americans suffer from the distressing symptoms related to dementia and this number that will triple by 2050.
- Conditions
- Dementia, Primary Palliative Care, Mild Cognitive Impairment
- Trial name
- NCT03881579
- Testing
- nurse-led supportive care assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Stanford University
Parkinson Disease, Alzheimer Disease
Autoimmune Features of Neurodegenerative Disorders
This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD).
- Conditions
- Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT04239079
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Columbia University
MCI, Mild Cognitive Impairment
Telehealth-Adapted Compensatory Training and Intervention for Cognition
The goal of this clinical trial is to develop a five-week virtual cognitive training intervention for people with Mild Cognitive Impairment (MCI) based off an existing eight-week intervention.
- Conditions
- MCI, Mild Cognitive Impairment, Mild Cognitive Impairment (MCI)
- Trial name
- TACTIC (NCT07366346)
- Testing
- Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT-MCI), Brief Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (bME-CCT-MCI)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Florida
Parkinson Disease, Mild Cognitive Impairment
Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson Disease
The study is a randomized, double-blind, sham-controlled cross-over trial to assess the efficacy as well as safety and tolerability of auditory SWS enhancement on measured outcomes in Parkinson disease (PD) patients with…
- Conditions
- Parkinson Disease, Mild Cognitive Impairment, Huntington Disease
- Trial name
- NCT04589182
- Testing
- MHSL- SleepBand
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Christian Baumann
Overactive Bladder, Mild Cognitive Impairment
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive…
- Trial name
- NCT02240459
- Testing
- fesoterodine 4mg, Oxybutynin, fesoterodine 8mg
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- University of Alberta
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - 3-Week Aptar CPS Device
The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body.
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset
- Trial name
- NCT05006599
- Testing
- Insulin (Humulin® R U-100), Aptar Pharma CPS Intranasal Delivery Device
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Alzheimer Disease, Mild Cognitive Impairment
Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects
The primary objective of this study is to demonstrate that individuals with low short-term practice effects (STPE) on cognitive testing are more likely to be identified as "positive" on amyloid imaging than individuals with high…
- Trial name
- APPE (NCT03466736)
- Testing
- [18F]flutemetamol PET scan
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- University of Utah
Mild Cognitive Impairment
Effect of Ginkgo Biloba Special Extract LI 1370 on Dual-tasking in Patients With MCI
The aim of this study is to evaluate the effects of Ginkgo Biloba Extract (GBE) in executive function-impaired Mild Cognitive Impairment (MCI) patients by assessing gait while walking alone as well as under differing dual-task…
- Trial name
- NCT01046292
- Testing
- Ginkgo biloba
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Basel, Switzerland
Mild Cognitive Impairment
Effects of Telerehabilitation on Brain Network Connectivity
The current project aims at assessing the impact of various cognitive telerehabilitation approaches on patients with Mild Cognitive Impairment (MCI) associated with neurodegenerative diseases, namely Alzheimer's disease (AD) and…
- Trial name
- NCT06278818
- Testing
- Cognitive Telerehabilitation, Control Condition
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- University of Pavia
Mild Cognitive Impairment
Filipino Multicomponent Intervention to Maintain Cognitive Performance in High Risk Population (FINOMAIN)
FINOMAIN is a community-based, cluster randomized controlled trial (cRCT) of dance intervention INDAK and standardized vascular care.
- Trial name
- FINOMAIN (NCT04301544)
- Testing
- INDAK (Improving Neurocognition through Dance and Kinesthetics), Nutrition Counseling, Standardized Vascular Care
- Where
- Philippines
- Volunteers
- 72 people
- Sponsor
- St. Luke's Medical Center, Philippines
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.